Mallinckrodt (MNK) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
2 Dec, 2025Executive summary
The 2025 Annual General Meeting is scheduled for May 15, 2025, in Dublin, Ireland, with shareholders voting on director elections, auditor re-appointment, and executive compensation.
Key 2024 performance highlights include $1.98 billion in net sales, a 47% reduction in principal debt, and successful product launches and divestitures.
The company emerged from bankruptcy in late 2023, adopting new governance documents and a revised board and executive compensation structure.
Voting matters and shareholder proposals
Shareholders will vote on the election of five directors, the re-appointment of PricewaterhouseCoopers LLP as independent auditors, and an advisory say-on-pay vote for executive compensation.
All proposals require a simple majority of votes cast; abstentions and broker non-votes do not affect outcomes.
Shareholder proposals for the 2026 AGM must be submitted between February 14 and March 16, 2026.
Board of directors and corporate governance
The board consists of the CEO, two designated directors, and four independent directors nominated by a Nominating and Selection Committee.
Recent governance changes include a new memorandum and articles of association and updated committee charters post-bankruptcy.
The board has four standing committees: Audit, Governance and Compliance, Human Resources and Compensation (HRCC), and Transaction Review.
Directors are elected for one-year terms by majority vote; the chair and CEO roles are separated.
Latest events from Mallinckrodt
- Branded product growth and merger drive 2025 outlook, with sales guided up to $3.62B.MNK
Q2 202516 Feb 2026 - Q3 2025 net sales up 49% to $753.1M, led by Acthar Gel growth and Endo merger contributions.MNK
Q3 202513 Feb 2026 - Q2 sales up 8.3%, guidance raised, and Therakos sale to reduce net debt by 50%+.MNK
Q2 20242 Feb 2026 - Net sales rose, losses narrowed, and Therakos sale will cut net debt by over 60%.MNK
Q3 202416 Jan 2026 - Restructuring, innovation, and focused growth drive strong performance and lower debt.MNK
Jefferies London Healthcare Conference 202413 Jan 2026 - Merger forms a pharma leader with $3.6B revenue, $150M synergies, and strong 2024 results.MNK
Q4 202426 Dec 2025 - Merger forms a $6.7B global pharma leader with $150M annual synergies and NYSE listing planned.MNK
M&A Announcement26 Dec 2025 - Shareholders to vote on directors, auditors, and executive pay at the 2025 Annual Meeting.MNK
Proxy Filing2 Dec 2025 - EGM to vote on rebranding, major preferred share capital increase, and Board-recommended proposals.MNK
Proxy Filing2 Dec 2025